



FOR IMMEDIATE RELEASE

NIRvana Sciences Successfully Completes NCI Phase I SBIR

RESEARCH TRIANGLE PARK, NC, January 10, 2024 – NIRvana Sciences, Inc., a leading developer of multiplexable dyes, probes and contrast agents, today announced that it has successfully completed its Phase I SBIR grant from the National Cancer Institute (NCI) at the National Institutes of Health (NIH).

NIRvana Sciences and its collaborator successfully proved that its dyes performed well as a contrast agent for evaluating the impact of radiotherapy using photoacoustic imaging in small animal cancer studies. Photoacoustic imaging is an emerging In Vivo imaging technique that uses light to excite the contrast agent and doppler ultrasound for detection. This non-invasive imaging technique is being used to study how blood vessels grow in tumors, blood oxygenation mapping, functional brain mapping, skin melanoma detection and more.

“NIRvana is excited to be developing new In Vivo contrast agents for the rapidly advancing field of photoacoustic imaging. The superior performance of this first agent against market-leading agent bodes well for NIRvana’s continued development of a larger assortment of targeted and non-targeted agents” says CEO Russell Thomas.

About NIRvana Sciences

NIRvana Sciences is a spin-out from North Carolina State University with a mission to commercialize red and near-infrared fluorescent dyes and associated probes with narrow spectral properties for use in life science applications. In addition to support from NIH, NIRvana has also received support from angel investors in North and South Carolina, North Carolina Biotechnology Center (NCBC), and NC IDEA. NIRvana facility is located at Alexandria Innovation Center in Research Triangle Park, NC USA.

For additional information, please visit www.nirvanasciences.com

Contact:

NIRvana Sciences, Inc.
Russell Thomas
919.354.1053
Russell@nirvanasciences.com